Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, announced positive results from cohort 4 of the randomized, blinded, placebo-controlled Phase 1 clinical trial ...
Adding radiation therapy to systemic therapy for patients with advanced liver cancer can extend overall survival and delay tumor progression without compromising patients' quality of life, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback